论文部分内容阅读
目的探讨雷帕霉素药物洗脱支架在老年冠心病经皮冠状动脉介入治疗中应用的安全性和有效性。方法入选320例冠心病患者,分为国产雷帕霉素药物洗脱支架组(Firebird组)160例,进口雷帕霉素药物洗脱支架组(Cypher组)160例。比较两组置入支架后6个月随访时的临床不良事件和再狭窄率。结果Firebird组共置入支架197枚,Cypher组共置入支架204枚。临床6个月随访示Firebird组临床不良事件3例,Cypher组4例,差异无显著性意义。6个月期随访造影显示Firebird组(66例)和Cypher组(77例)支架内再狭窄各出现1例。结论雷帕霉素药物洗脱支架Firebird和Cypher类似,而且Firebird有更高的效价比。
Objective To investigate the safety and efficacy of rapamycin-eluting stent in percutaneous coronary intervention in elderly patients with coronary heart disease. Methods A total of 320 patients with coronary heart disease were enrolled. They were divided into 160 cases (Firebird group) and 160 cases (Cypher group) with imported rapamycin eluting stent group (Cypher group). Clinical adverse events and restenosis rates at 6-month follow-up were compared between the two groups. Results A total of 197 scaffolds were placed in the Firebird group, and a total of 204 scaffolds were placed in the Cypher group. Clinical 6 months follow-up showed Firebird group of clinical adverse events in 3 cases, Cypher group 4 cases, no significant difference. Six-month follow-up angiography showed 1 case of stent restenosis in Firebird group (66 cases) and Cypher group (77 cases). Conclusion The rapamycin-eluting stent Firebird is similar to Cypher, and Firebird has a higher titer.